PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
In summary, our research showed that PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors and suggests that PDE4 inhibition is a novel therapeutic option for treatment of BRAF-mutated melanoma patients.
Authors
- Samia Mourah (ORCID: https://orcid.org/0000-0002-9283-1068)
- Mélanie Bernard-Cacciarella
- Célèste Lebbé (ORCID: https://orcid.org/0000-0002-5854-7290)
- Coralie Reger de Moura (ORCID: https://orcid.org/0000-0002-3728-6722)
- Baptiste Louveau (ORCID: https://orcid.org/0000-0001-5411-3893)
- Selma Becherirat
- Nicolas Dumaz (ORCID: https://orcid.org/0000-0003-3511-2160)
- Julie Delyon (ORCID: https://orcid.org/0000-0002-4557-3377)
- Anissa Roger (ORCID: https://orcid.org/0000-0002-0777-600X)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Saint-Louis (FR)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1186/s12964-024-01941-y
- Citations
- 4
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.94